Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with a trial fibrillation

American Journal of Cardiovascular Drugs

Volumn 11, Issue 4, 2011, Pages 265-275

  Deedwania, Prakash C ^a   Huang, Grace W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulants; Apixaban; Atrial fibrillation; Dabigatran etexilate; Edoxaban; Factor Xa inhibitors; Rivaroxaban; Stroke; Thrombin inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CARDIOEMBOLISM; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; EMBOLISM; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOEMBOLISM;

EID: 79960282290     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11592410-000000000-00000     Document Type: Review

References (42)

1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995 Mar 13; 155 (5): 469-73
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001 May 9; 285 (18): 2370-5 (Pubitemid 32424106)
3. American Heart Association Heart Disease and Stroke Statistics Writing Group. Executive summary: heart disease and stroke statistics. 2011 update: a report from the American Heart Association. Circulation 2011 Feb; 123 (4): 459-63
4. Yamanouchi H, Tomonaga M, Shimada H, et al. Nonvalvular atrial fibrillation as a cause of fatal massive cerebral infarction in the elderly. Stroke 1989; 20 (12): 1653-6 (Pubitemid 20030873)
5. Lakshminarayan K, Solid CA, Collins AJ, et al. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002). Stroke 2006; 37 (8): 1969-74 (Pubitemid 44309888)
6. Deedwania PC, Lardizabal JA. Atrial fibrillation in heart failure: a comprehensive review. Am J Med 2010; 123 (3): 198-204
7. van Walraven WC, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003; 163: 936-43 (Pubitemid 36519739)
8. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70 (Pubitemid 32537350)
9. Kim YD, ChaMJ, Kim J, et al. Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. Stroke. Epub 2011 Feb 24
10. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-72
11. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124
12. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12 (10): 1360-420
13. European Heart Rhythm Association, European Association for Cardio- Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010 Oct 31, 19: 2369-429
14. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999 Oct 5; 131 (7): 492-501 (Pubitemid 29482392)
15. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010 Jul; 123 (7): 638-45
16. Health Canada. Warfarin interactions with drugs, herbs and food [online]. Available from URL: http://www.enotalone.com/article/10268.html/ [Accessed 2010 Nov 1]
17. Weitz JI. New oral anticoagulants in development. ThrombHaemost 2010 Jan; 103 (1): 62-70
18. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005 May 23; 165 (10): 1095-106 (Pubitemid 40720733)
19. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367 (9526): 1903-12
20. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360 (20): 2066-78
21. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57 (2): 223-42
22. Turpie AGG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2007; 29: 155-65
23. Ahrens I, Lip GYH, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60
24. Sobieraj-Teague M, ODonnellM, Eikelboom J. New anticoagulants for atrial fibrillation. Sem Thromb Hemost 2009; 35: 515-24
25. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin inpatients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51
26. Mahaffey K. Stroke prevention using the oral direct Factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF) [online]. Available from URL: http://my. americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documen ts/downloadable/ucm-426788.pdf [Accessed 2011 May 13]
27. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17
28. Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor Xa inhibitor. Drugs 2011; 71; In press
29. Garnock-Jones KP. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs 2011; 11 (1): 57-72
30. Boehringer Ingelheim Pharma GmbH & Co. Pradaxa- (dabigatran etexilate) Prescribing information [online]. Available from URL: http://www.pradax apro.com/ [Accessed 2011 Jan 3]
31. Beasley BN, Unger EF, Temple R. Anticoagulant options: why the FDA approved a higher but not a lower dose of dabigatran. N Engl JMed 2011 May 12; 364 (19): 1788-90
32. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57 (11): 1330-7
33. Duggan ST, Scott LJ, Plosker GL. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs 2009; 69 (13): 1829-51
34. Bayer Schering Pharma AG. Xarelto- (rivaroxaban): summary of product characteristics [online]. Available from URL: http://www.xarelto.com/html/ downloads/Xarelto-Summary-of-Product-Characteristics-May2009.pdf [Accessed 2011 Jan 3]
35. Bereznicki LRE, Peterson GM. New antithrombotics for atrial fibrillation. Cardiovasc Ther 2010 Oct; 28 (5): 278-86
36. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010 Mar; 159 (3): 340-7
37. Eikelboom JW, ODonnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010 Mar; 159 (3): 348-53
38. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation: (ARISTOTLE) trial - design and rationale [published erratum appears in Am Heart J 2010 Jun; 159 (6): 1162]. Am Heart J 2010 Mar; 159 (3): 331-9
39. Edoxaban tosylate. Am J Cardiovasc Drugs 2011; 11(2): 129-35
40. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factorXa inhibitor, with warfarin for stroke prevention in patientswith atrial fibrillation. Thromb Haemost 2010 Sep; 104 (3): 633-41
41. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010 Oct; 160 (4): 635-41
42. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154 (1): 1-11